CES1 and melanoma: To confirm the efficacy of the in vivo Ces1 inhibition, we conducted ex vivo ABPP on both melanoma and skin samples, showing that Ces1 was effectively inhibited in the JZL184-treated group, indicated by a clear reduction in the ex vivo ABPP(Fig. 5C,D).